The elements of an effective compliance program provide a framework for life sciences companies to ensure their program is comprehensive and practicable. These same elements can be tailored to create an effective compliance training program for transparency reporting. By applying this framework to your transparency training, companies can enhance compliance with transparency reporting obligations, ensuring […]
In recent years, anti-bribery and anti-corruption enforcement penalties have been increasing in number and size, and recent actions illustrate that third parties continue to be a concern. For life sciences companies, managing these risks is crucial to complying with laws such as the US Anti-Kickback Statute, the Foreign Corrupt Practices Act and the UK Bribery […]
The transparency landscape for the life science industry is continuously evolving, with requirements that seem to be increasing by the minute. At Informa’s recent Transparency, Aggregate Spend & HCP Engagement conference, industry professionals discussed the latest regulations impacting both pharmaceutical and medical device companies. Two areas stood out during these discussions: Illinois and Brazil.
Illinois
House Bill 5517 […]
At Informa’s recent Transparency, Aggregate Spend & HCP Engagement conference, compliance professionals focused heavily on the CMS audits that began in early 2023. Since data collection began in 2013, the CMS’s decision to perform random audits marks a pivotal shift, signaling a new phase in Sunshine Act reporting. Throughout the conference, valuable insights were […]
At Informa’s recent Transparency, Aggregate Spend & HCP Engagement conference, compliance professionals focused heavily on the CMS audits that began in early 2023. Since data collection began in 2013, the CMS’s decision to perform random audits marks a pivotal shift, signaling a new phase in Sunshine Act reporting. Throughout the conference, valuable insights were […]
On Friday, June 28, 2024, the Centers for Medicare and Medicaid Services (CMS) published the 2023 Open Payments data, along with newly submitted and updated payment records for program years 2017-2022. The 2023 data includes transactions from January 1st to December 31st. Applicable manufacturers reported $12.75 billion in reportable payments, ownership and investment interests to […]
MediSpend experts recently presented a webinar focused on the ever-evolving life science transparency regulations around the world. They discussed the newly released Connecticut pharmaceutical sales representative disclosure report, along with recent transparency updates in Denmark and India. The presentation concluded with the status of requirements in Italy and the United Kingdom.
Public Act 23-171 was signed […]
The global compliance landscape is challenging and constantly evolving. Business complexity is increasing, and enforcement risks are intensifying. As a result, we must continuously assess whether we have the tools necessary to proactively identify and manage risks, and ensure these tools engage the entire organization in the compliance process. Understanding our compliance data is becoming […]
May 22, 2024
Revolutionizing Commercial Compliance for Life Sciences:
MediSpend’s Strategic Acquisition of MedCompli
Portsmouth, NH May 22, 2024 — MediSpend, a global technology company providing best-in-class solutions for the life sciences industry, is thrilled to announce its acquisition of MedCompli, a compliance software solutions provider focused on simplifying life science compliance management. This strategic move […]
For pharmaceutical and medical device manufacturers of all sizes, it is important to stay on top of the latest transparency reporting regulations and HCP/O engagement rules. As a leading provider of transparency reporting and paid HCP engagement management solutions, MediSpend also offers our Legislative Watch to help keep you up-to-date on related legislation.
In this webinar, […]
